BioSpace News Archive

New data from Eli Lilly and Company’s (NYSE: LLY) monarchE study for an investigational use of Verzenio® (abemaciclib), in combination with endocrine therapy, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) high risk early breast cancer will be presented at the October 14 European Society for Medical Oncology (ESMO) Virtual Plenary.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster presentation will be given at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021

Semler Scientific, Inc. today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has approved the listing of its ommon stock on the exchange. Semler Scientific’s common stock will begin trading on The Nasdaq Capital Market under the trading symbol “SMLR” at the open of the market on Tuesday, September 28, 2021.

Life Sciences Ontario has released a bold new vision for how the Ontario government can create a provincial rare disease strategy to save lives and boost Ontario’s economy.

Eyevensys today announces it has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology.

Cortexyme, Inc. today announced that it will participate at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD 2021) conference scheduled for November 9-12, 2021, in Boston, Massachusetts, as well as virtually.

Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”) and Intract Pharma (“Intract”) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intract’s Soteria® and Phloral® drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.

PDS Biotechnology Corporation today announced that its management will participate in the Benzinga Healthcare Small Cap Conference.

Acasti Pharma Inc. today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of intravenous (IV) GTX-104 compared to currently marketed oral nimodipine capsules in 50 healthy subjects.

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that Zebra Medical Vision secures 8th 510K FDA clearance for its Coronary Artery Calcium solution as part of its population health offering.